Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin

Nicla La Verde, Sheila Piva, Monica Ganzinelli, Gabriella Farina, Giorgio Gherardi, Serena Girelli, Annalisa Bramati, Luca Del Re, Giovanna Damia

Research output: Contribution to journalArticle

Abstract

Eribulin mesylate is approved for the treatment of metastatic breast cancer after progression with anthracyclines and taxanes. Here we report the case of a woman with triple-negative breast cancer who, after nine lines of chemotherapy, showed striking primary tumor shrinkage and regression of metastatic lesions with eribulin treatment. This response allowed the patient to undergo debulking surgery. Even though the patient was heavily pretreated, eribulin was well tolerated and improved her quality of life. Biological analysis of tumor specimens was performed to investigate the underlying mechanism of action of the drug.

Original languageEnglish
Pages (from-to)1703-1709
Number of pages7
JournalFuture Oncology
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 2013

Keywords

  • eribulin
  • metastatic breast cancer
  • triple negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin'. Together they form a unique fingerprint.

  • Cite this

    La Verde, N., Piva, S., Ganzinelli, M., Farina, G., Gherardi, G., Girelli, S., Bramati, A., Del Re, L., & Damia, G. (2013). Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin. Future Oncology, 9(11), 1703-1709. https://doi.org/10.2217/fon.13.169